Phaseline

Companies › CereMark Pharma

CereMark Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[F-18]Flornaptitril
Tau imaging agent (positron emission tomography tracer)
–Phase 3Alzheimer DiseaseJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06254469[F-18]FlornaptitrilPhase 3Alzheimer DiseaseNeurologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.